Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.
Álvaro López-díaz, Manuel Murillo-Izquierdo, Elisa Moreno-Mellado
The British journal of psychiatry : the journal of mental science August 1, 2019 DOI: 10.1192/bjp.2019.102 via PubMed
Summary
AI-generated from the abstractIn European public health systems, ketamine therapy for treatment-resistant depression should only be considered after all guideline-recommended antidepressant strategies have been tried. The paper describes the ethical, regulatory, and procedural rules governing the off-label use of ketamine in such settings.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Depression Ketamine |
| Keywords | Antidepressants |
| Citations | 21 |
| Key finding | Ketamine therapy for treatment-resistant depression in European national health systems should only be considered after all evidence-based antidepressant strategies in clinical guidelines have been attempted. |
Abstract
Ketamine therapy for treatment-resistant depression in European national health systems may only be considered after attempting all evidence-based antidepressant strategies outlined in clinical guidelines. This paper seeks to explain the ethical, regulatory and procedural framework for the off-label use of ketamine for treatment-resistant depression within a public healthcare system.Declaration of interestNone.